Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XILLIX FDA APPROVED -- Ignore unavailable to you. Want to Upgrade?

To: Edward W. Richmond who wrote (437)	7/19/1999 3:22:00 AM
From: hsg	Respond to of 572

Thanks for doing this DD...I was surprised by the news of lower revenues...analyst reports I have seen have not accounted for any of this...the technology/product is fantastic...marketing...MAJOR disappointment. I got in recently (actually had a small piece of the IPO years ago) and may buy more if the price dips...I think that the stock/company still has untapped potential....but has disappointed so far...mabye they are being conservative with their revenue estimates??? I gained NO confidence in the stock after talking to the PR person...mabye they need a change there....(just get us the revenues XLX!!!)...

To: Edward W. Richmond who wrote (437)	7/19/1999 11:02:00 AM
From: Garry K.	Read Replies (2) \| Respond to of 572

Like many other Xillix shareholders, I feel Olympus is at total control of the helm....they seem to move at their own pace and have their own objectives. Perhaps if Olympus wants control of Xillix's technology, they should pay for it in the form of a takeover. Pay the Xillix shareholder a fair price for the stock, and they can do whatever they want with the technology -- incorporate it into their own product lines, develop the second generation products themselves, or shelve it. Any comments out there? Garry